Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...

A federal judge in Texas has upheld the U.S. Food and Drug Administration's decision to remove Novo Nordisk's blockbuster drugs Ozempic and Wegovy from the drug shortage list, rejecting a challenge ...

Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus ...

Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

The clinical trial underscores Innovent’s ambition to deliver innovative obesity treatment to patients across Asia.

Lilly’s announcement Tuesday focused on single-dose vials for people paying out of pocket for the two lowest doses of Zepbound, priced at $399 and $549, and did not mention the savings-card ...